This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Glaucoma medications and ocular surface disease

Glaucoma medications and ocular surface disease
Reviewed by Su Young

3 August 2023 | Su Young | EYE - Glaucoma | Drug allergy, OSD, drug toxicity, drug-induced cicatricial keratitis, dry eye, glaucoma medications, ocular surface disease
Share This

This literature review examined ocular surface disease (OSD) associated with glaucoma medication. The authors examined the prevalence of features and management guidelines glaucoma medication associated OSD. Fifty-eight articles published within the past five years are included in this review and the following themes are covered: preservatives in glaucoma medication (such as benzalkonium chloride (BAK), Purite, Polyquaternium-1 (Polyquad) and Sofzia). BAK is the most common preservative used with toxic effects on the ocular surface cells, cornea, conjunctiva, and trabecular cells. Purite is a newer generation preservative that is better tolerated with lesser toxic effects. Polyquad is a polymeric quaternary ammonium molecule that has less cytotoxicity than BAK but can still decrease aqueous tear film production whilst Sofzia is an ionic-buffered preservative that induces less conjunctival inflammation and fewer corneal changes compared to BAK. Effects on ocular and periocular surfaces (such as contact dermatitis of the periocular region and eyelids being caused by topical beta-blockers and apraclonidine, and dorzolamide being associated with periorbital dermatitis, leading to fibrosis and ectropion). Prostaglandin analogues are associated with hypertrichosis and hyperpigmentation of the eyelashes as well as darkening of the skin on the eyelids. Carbonic anhydrase inhibitors can result in limbal conjunctival follicles, follicular conjunctivitis, and severe allergic conjunctivitis. Pilocarpine is associated with allergic conjunctivitis, squamous metaplasia, keratinization of the lid margins, a reduction in the density of goblet cells, and rarely cicatrization. Topical beta-blockers may increase fibroblasts and inflammatory cells in the conjunctiva, leading to squamous metaplasia and fibrosis and caution for alternative diagnosis (mucus membrane pemphigoid, Stevens Johnson Syndrome and ocular pemphigus vulgaris are other differential diagnoses which share clinical features with the above and should be considered). The review also highlights that long-term multiple glaucoma medication usage is associated with a high risk of trabeculectomy failure. The reviewers recommend thorough assessment at review not only of the glaucoma but for OSD. In addition, choosing combination- and preservative-free medications can decrease dosing and side-effects. With adverse effects, changing medication class, using anti-inflammatory agents, lubricants and reducing preservative exposure can improve compliance, quality of life and preserve vision.

Ocular surface disease and anti-glaucoma medications: various features, diagnosis, and management guidelines.
Andole S, Senthil S.
SEMINARS IN OPHTHALMOLOGY
2023;38(2):158-66.
Share This
Su Young
CONTRIBUTOR
Su Young

Tennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency